Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950881 | 1.00 | NR4A2 (0.57) | NR4A2PIM1PIM3CYP2A6CREBBP | |
| SCHEMBL14070635 | 0.85 | NR4A2 (0.53) | NR4A2PIM1PIM3CREBBPALDH1A1 | |
| SCHEMBL14072599 | 0.85 | NR4A2 (0.53) | NR4A2PIM1PIM3CREBBPALDH1A1 | |
| SCHEMBL27988710 | 0.83 | CYP2A6 (0.50) | NR4A2PIM1PIM3CYP2A6CREBBP | |
| SCHEMBL6621360 | 0.82 | CYP2A6 (0.49) | NR4A2PIM1PIM3CYP2A6CREBBP | |
| SCHEMBL5002752 | 0.81 | CYP2A6 (0.58) | NR4A2PIM1PIM3CYP2A6ALDH1A1 | |
| SCHEMBL29953523 | 0.81 | CYP2A6 (0.58) | NR4A2PIM1PIM3CYP2A6ALDH1A1 | |
| SCHEMBL5008074 | 0.81 | CYP2A6 (0.58) | NR4A2PIM1PIM3CYP2A6ALDH1A1 | |
| SCHEMBL9485678 | 0.80 | BRAF (0.50) | NR4A2PIM1PIM3CREBBPALDH1A1 | |
| SCHEMBL30561554 | 0.80 | BRAF (0.50) | NR4A2PIM1PIM3CREBBPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | DELIX THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-107873030-B | 5-HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10392390-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3288946-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20180186797-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3288946-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| WO-2016176177-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| CN-1342161-A | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMA (US) | 2002-03-27 | — | — | CN | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| EP-1140936-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| WO-2000042040-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0946519-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024771-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-11 | — | — | WO | disclosed |
| US-5272143-A | 6-oxoazepinoindole compounds, and pharmaceutical compositions containing them | KALI-CHEMIE PHARMA GMBH (DE) | 1993-12-21 | — | — | US | disclosed |
| US-3978066-A | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives | AYERST, MCKENNA AND HARRISON LTD. (CA) | 1976-08-31 | — | — | US | disclosed |
| US-3950343-A | PYRROLOISOQUINOLINE DERIVATIVES | AYERST, MCKENNA AND HARRISON LTD. (CA) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295106-A1 | ERGOLINE-LIKE COMPOUNDS FOR PROMOTING NEURAL PLASTICITY | GRIN1, GRIN2A, GRIN3B | NR4A2 345/4885PIM1 3878/4885PIM3 3882/4885 |
| US-10392390-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | NR4A2 330/4885PIM1 4325/4885PIM3 3755/4885 |
| US-20180186797-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | NR4A2 330/4885PIM1 4325/4885PIM3 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.